Progressive white matter injury in preclinical Dutch cerebral amyloid angiopathy

Authors

Zahra Shirzadi
Wai Ying W. Yau
Stephanie A. Schultz
Aaron P. Schultz
Matthew R. Scott
Maged Goubran
Parisa Mojiri-Forooshani
Nelly Joseph-Mathurin
Kejal Kantarci
Greg Preboske
Marieke J. H. Wermer
Clifford Jack
Tammie Benzinger
Kevin Taddei, Edith Cowan UniversityFollow
Hamid R. Sohrabi
Reisa A. Sperling
Keith A. Johnson
Randall J. Bateman
Ralph N. Martins, Edith Cowan UniversityFollow
Steven M. Greenberg
Jasmeer P. Chhatwal
DIAN Investigators

Document Type

Journal Article

Publication Title

Annals of Neurology

Volume

92

Issue

3

First Page

358

Last Page

363

PubMed ID

35670654

Publisher

Wiley

School

Centre of Excellence for Alzheimer's Disease Research and Care / School of Medical and Health Sciences

RAS ID

52193

Funders

National Institute on Aging. Grant Numbers: UF1AG032438; K23AG049087; P01AG036694, P01AG036694, K23AG049087, UF1AG032438

National Institute of Health. Grant Numbers: S10RR023043, S10RR023401, S10RR021110

National Institutes of Health (NIH)

National Institute of Biomedical Imaging and Bioengineering

Massachusetts General Hospital

Center for Biomedical Imaging

National Health and Medical Research Council

Alzheimer's Society of Canada

National Institute of Neurologic Diseases and Stroke. Grant Number: R01NS070834

Grant Number

NHMRC Number : APP1129627

Grant Link

http://purl.org/au-research/grants/nhmrc/1129627

Comments

Shirzadi, Z., Yau, W. Y. W., Schultz, S. A., Schultz, A. P., Scott, M. R., Goubran, M., ... & DIAN Investigators. (2022). Progressive white matter injury in preclinical Dutch cerebral amyloid angiopathy. Annals of Neurology, 92(3), 358-363.

https://doi.org/10.1002/ana.26429

Abstract

Autosomal-dominant, Dutch-type cerebral amyloid angiopathy (D-CAA) offers a unique opportunity to develop biomarkers for pre-symptomatic cerebral amyloid angiopathy (CAA). We hypothesized that neuroimaging measures of white matter injury would be present and progressive in D-CAA prior to hemorrhagic lesions or symptomatic hemorrhage. In a longitudinal cohort of D-CAA carriers and non-carriers, we observed divergence of white matter injury measures between D-CAA carriers and non-carriers prior to the appearance of cerebral microbleeds and > 14 years before the average age of first symptomatic hemorrhage. These results indicate that white matter disruption measures may be valuable cross-sectional and longitudinal biomarkers of D-CAA progression. ANN NEUROL 2022;92:358–363.

DOI

10.1002/ana.26429

Access Rights

subscription content